OrbiMed Genesis GP LLC
CIK 1808744 · last filed 2026-06-15
OrbiMed Genesis GP LLC is a corporate insider who has filed 24 SEC Form 4 insider transactions across 14 companies since 2021. The most recent filing, for STTK, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$29.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $813.8M across reported positions. The firm reports its address in New York, NY. 103 SEC filings were submitted jointly with ORBIMED ADVISORS LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$813.79M
14
24
-$29.17M
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STTK | Director | 1,051,021 | $6.20 | $6.52M | $0 | 2 | 2026-06-15 |
| QTTB | Director | 625,000 | $11.10 | $6.94M | $45.00M | 1 | 2026-06-01 |
| IMA | Director | 753,062 | $5.08 | $3.83M | $0 | 2 | 2026-04-16 |
| EWTX | Director | 14,809,075 | $44.40 | $657.52M | $30.00M | 1 | 2025-04-04 |
| IRON | Director | 746,171 | $70.06 | $52.28M | -$12.57M | 2 | 2025-03-26 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 7,663,349 | $14.59 | $111.81M | -$68.63M | 2 | 2024-05-20 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 2,270,930 | $64.97 | $147.54M | -$86.02M | 1 | 2023-12-29 |
| PMVP | 10%+ Owner | 6,475,291 | $1.40 | $9.07M | -$587.3K | 1 | 2023-11-24 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 25,242 | $28.69 | $724.2K | -$5.44M | 4 | 2023-08-17 |
| CMPX | Director | 15,219,994 | $2.00 | $30.44M | $5.13M | 2 | 2022-11-10 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 0 | $54.99 | $0 | $0 | 1 | 2022-07-01 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 174,841 | $17.16 | $3.00M | -$3.38M | 1 | 2022-06-24 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 16,384,235 | $4.06 | $66.52M | $31.33M | 2 | 2022-01-13 |
| JANX | Director | 2,760,366 | $17.10 | $47.20M | $36.00M | 1 | 2021-06-16 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | STTK | Buy (P) | — | $0 | EDGAR |
| 2026-06-09 | STTK | Conv (C) | — | $0 | EDGAR |
| 2026-06-01 | QTTB | Buy (P) | +5,625,000 | $45.00M | EDGAR |
| 2026-04-16 | IMA | Buy (P) | — | $0 | EDGAR |
| 2025-07-30 | IMA | Grant (A) | +250,833 | $624.6K | EDGAR |
| 2025-04-04 | EWTX | Buy (P) | +1,490,313 | $30.00M | EDGAR |
| 2025-03-26 | IRON | Sell (S) | −22,952 | -$1.24M | EDGAR |
| 2025-03-21 | IRON | Sell (S) | −209,716 | -$11.33M | EDGAR |
| 2024-05-20 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −3,099,900 | -$68.63M | EDGAR |
| 2023-12-29 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Sell (S) | −4,639,041 | -$86.02M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.